Halozyme Therapeutics Inc (HALO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH44899D
- Pages: 60
- November 2018
- Total Views:1211
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Halozyme Therapeutics Inc (Halozyme) is a biotechnology company that develops and commercializes novel recombinant human enzymes to provide innovative products for cancer, dermatology, diabetes and drug delivery markets. The company's marketed product, Hylenex is an agent for drug and fluid infusion. Its pipeline products include analog insulin PH20, for the treatment of diabetes; PEGPH20, for the treatment of pancreatic cancer; and HTI-501, for the treatment of scarring, among others. Its products are based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes affecting the extracellular matrix. Its Enhanze technology is a novel drug delivery platform proposed to enhance the absorption and dispersion of biologics. The company has partnerships with Pfizer, Roche, Baxter and Intrexon for the development and commercialization of drugs. Halozyme is headquartered in San Diego, California, the US.
Halozyme Therapeutics Inc (HALO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Halozyme Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 12
Licensing Agreements 13
Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 13
Bristol-Myers Squibb and Halozyme Therapeutics Enter into License Agreement 14
Roche Enters into Licensing Agreement with Halozyme Therapeutics 15
Halozyme Therapeutics Enters into Licensing Agreement with Eli Lilly and Company 16
Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 17
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 18
Pfizer Enters Into Licensing Agreement With Halozyme Therapeutics To Develop Biologics 19
Equity Offering 20
Halozyme Therapeutics Raises USD143.8 Million in Public Offering of Shares 20
Halozyme Therapeutics Completes Public Offering Of Shares For USD 115 Million 22
Halozyme Completes Public Offering Of Common Stock For USD 83 Million 23
Halozyme Therapeutics Inc-Key Competitors 25
Halozyme Therapeutics Inc-Key Employees 26
Halozyme Therapeutics Inc-Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Nov 06, 2018: Halozyme reports third quarter 2018 financial results 28
Aug 08, 2018: Halozyme reports second quarter 2018 results 30
May 10, 2018: Halozyme Reports First Quarter 2018 Results 31
Feb 20, 2018: Halozyme Reports Fourth Quarter And Full-Year 2017 Results 32
Nov 07, 2017: Halozyme Reports Third Quarter 2017 Results 33
Aug 08, 2017: Halozyme Reports Second Quarter 2017 Results 35
May 09, 2017: Halozyme Reports First Quarter 2017 Financial Results 36
Feb 28, 2017: Halozyme Reports Fourth Quarter And Full Year 2016 Financial Results 37
Corporate Communications 39
Sep 05, 2018: Halozyme appoints Benjamin Hickey as Chief Commercial Officer 39
Product News 40
11/10/2017: Halozyme To Present Nonclinical Data At SITC 2017 Supporting Combination Of PEGPH20 With Checkpoint Inhibitors 40
10/24/2017: First Gastric Cancer Patient Dosed In Clinical Trial Collaboration Evaluating Halozymes PEGPH20 In Combination With Anti-PDL1 Immunotherapy 41
10/16/2017: Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer Patients 42
07/13/2017: Initiation Of Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PDL1 Immunotherapy 43
06/04/2017: Experimental drug makes some pancreatic cancers more vulnerable to chemo 44
05/31/2017: Clinical trial shows experimental drugs ability to knock down pancreatic cancers defense 46
03/30/2017: Halozyme Provides Update On SWOG Collaborative Group Clinical Study 48
01/09/2017: Halozyme Provides Program Updates, 2017 Financial Guidance At 35th Annual JP Morgan Healthcare Conference 49
Clinical Trials 50
Jun 28, 2017: Halozyme Phase 2 Data In Advanced Pancreas Cancer Presented At European Society For Medical Oncology Symposium 50
Jun 04, 2017: Halozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO 52
May 17, 2017: Halozyme Phase 2 Data In Advanced Pancreas Cancer To Be Featured In An Oral Presentation At ASCO 54
Apr 03, 2017: Halozyme's PEGPH20 Increases Immune Response and Effectiveness of Immunotherapies in Preclinical Cancer Models 56
Jan 05, 2017: Halozyme Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints 58
Other Significant Developments 59
Jan 09, 2018: Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60
List Of Figure
List of Figures
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Halozyme Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Halozyme Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Halozyme Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 12
Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 13
Bristol-Myers Squibb and Halozyme Therapeutics Enter into License Agreement 14
Roche Enters into Licensing Agreement with Halozyme Therapeutics 15
Halozyme Therapeutics Enters into Licensing Agreement with Eli Lilly and Company 16
Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 17
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 18
Pfizer Enters Into Licensing Agreement With Halozyme Therapeutics To Develop Biologics 19
Halozyme Therapeutics Raises USD143.8 Million in Public Offering of Shares 20
Halozyme Therapeutics Completes Public Offering Of Shares For USD 115 Million 22
Halozyme Completes Public Offering Of Common Stock For USD 83 Million 23
Halozyme Therapeutics Inc, Key Competitors 25
Halozyme Therapeutics Inc, Key Employees 26
Halozyme Therapeutics Inc, Subsidiaries 27
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Halozyme Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Halozyme Therapeutics Inc (Halozyme) is a biotechnology company that develops and commercializes novel recombinant human enzymes to provide innovative products for cancer, dermatology, diabetes and drug delivery markets. The company's marketed product, Hylenex is an agent for drug and fluid infusion. Its pipeline products include analog insulin PH20, for the treatment of diabetes; PEGPH20, for the treatment of pancreatic cancer; and HTI-501, for the treatment of scarring, among others. Its products are based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes affecting the extracellular matrix. Its Enhanze technology is a novel drug delivery platform proposed to enhance the absorption and dispersion of biologics. The company has partnerships with Pfizer, Roche, Baxter and Intrexon for the development and commercialization of drugs. Halozyme is headquartered in San Diego, California, the US.
Halozyme Therapeutics Inc (HALO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Halozyme Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 12
Licensing Agreements 13
Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 13
Bristol-Myers Squibb and Halozyme Therapeutics Enter into License Agreement 14
Roche Enters into Licensing Agreement with Halozyme Therapeutics 15
Halozyme Therapeutics Enters into Licensing Agreement with Eli Lilly and Company 16
Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 17
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 18
Pfizer Enters Into Licensing Agreement With Halozyme Therapeutics To Develop Biologics 19
Equity Offering 20
Halozyme Therapeutics Raises USD143.8 Million in Public Offering of Shares 20
Halozyme Therapeutics Completes Public Offering Of Shares For USD 115 Million 22
Halozyme Completes Public Offering Of Common Stock For USD 83 Million 23
Halozyme Therapeutics Inc-Key Competitors 25
Halozyme Therapeutics Inc-Key Employees 26
Halozyme Therapeutics Inc-Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Nov 06, 2018: Halozyme reports third quarter 2018 financial results 28
Aug 08, 2018: Halozyme reports second quarter 2018 results 30
May 10, 2018: Halozyme Reports First Quarter 2018 Results 31
Feb 20, 2018: Halozyme Reports Fourth Quarter And Full-Year 2017 Results 32
Nov 07, 2017: Halozyme Reports Third Quarter 2017 Results 33
Aug 08, 2017: Halozyme Reports Second Quarter 2017 Results 35
May 09, 2017: Halozyme Reports First Quarter 2017 Financial Results 36
Feb 28, 2017: Halozyme Reports Fourth Quarter And Full Year 2016 Financial Results 37
Corporate Communications 39
Sep 05, 2018: Halozyme appoints Benjamin Hickey as Chief Commercial Officer 39
Product News 40
11/10/2017: Halozyme To Present Nonclinical Data At SITC 2017 Supporting Combination Of PEGPH20 With Checkpoint Inhibitors 40
10/24/2017: First Gastric Cancer Patient Dosed In Clinical Trial Collaboration Evaluating Halozymes PEGPH20 In Combination With Anti-PDL1 Immunotherapy 41
10/16/2017: Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer Patients 42
07/13/2017: Initiation Of Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PDL1 Immunotherapy 43
06/04/2017: Experimental drug makes some pancreatic cancers more vulnerable to chemo 44
05/31/2017: Clinical trial shows experimental drugs ability to knock down pancreatic cancers defense 46
03/30/2017: Halozyme Provides Update On SWOG Collaborative Group Clinical Study 48
01/09/2017: Halozyme Provides Program Updates, 2017 Financial Guidance At 35th Annual JP Morgan Healthcare Conference 49
Clinical Trials 50
Jun 28, 2017: Halozyme Phase 2 Data In Advanced Pancreas Cancer Presented At European Society For Medical Oncology Symposium 50
Jun 04, 2017: Halozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO 52
May 17, 2017: Halozyme Phase 2 Data In Advanced Pancreas Cancer To Be Featured In An Oral Presentation At ASCO 54
Apr 03, 2017: Halozyme's PEGPH20 Increases Immune Response and Effectiveness of Immunotherapies in Preclinical Cancer Models 56
Jan 05, 2017: Halozyme Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints 58
Other Significant Developments 59
Jan 09, 2018: Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60
List Of Figure
List of Figures
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Halozyme Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Halozyme Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Halozyme Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 12
Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 13
Bristol-Myers Squibb and Halozyme Therapeutics Enter into License Agreement 14
Roche Enters into Licensing Agreement with Halozyme Therapeutics 15
Halozyme Therapeutics Enters into Licensing Agreement with Eli Lilly and Company 16
Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 17
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 18
Pfizer Enters Into Licensing Agreement With Halozyme Therapeutics To Develop Biologics 19
Halozyme Therapeutics Raises USD143.8 Million in Public Offering of Shares 20
Halozyme Therapeutics Completes Public Offering Of Shares For USD 115 Million 22
Halozyme Completes Public Offering Of Common Stock For USD 83 Million 23
Halozyme Therapeutics Inc, Key Competitors 25
Halozyme Therapeutics Inc, Key Employees 26
Halozyme Therapeutics Inc, Subsidiaries 27
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Halozyme Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
: +91 99224 42855 
Related Reports
Page 108 | 
May 2021
Page 74 | May 2021
Page 130 | March 2021
Page 140 | November 2020
Page 99 | July 2020